01 / 18

Heart Failure
Longitudinal Care

Managing chronic heart failure over time: titrating guideline-directed therapy, monitoring volume status, and preventing readmission.

USMLE Step 3

What Is Heart Failure?

Heart failure (HF) is a chronic syndrome in which the heart cannot pump blood efficiently enough to meet the body's needs. It is not a single disease but the common endpoint of many cardiac conditions.

Defining Ejection Fraction

\( EF = \dfrac{\text{Stroke Volume}}{\text{End-Diastolic Volume}} \)
End-Diastolic (full) EDV End-Systolic (emptied) ESV contraction

Why Longitudinal Care Matters

HF is managed over months to years. Step 3 emphasizes the outpatient continuum: titrating medications to target doses, tracking symptoms, and catching decompensation early to prevent costly hospital readmissions.

High Readmission
~25% of HF patients are readmitted within 30 days of discharge.
Therapy Titration
GDMT must be uptitrated gradually over follow-up visits.
Mortality Benefit
Proper longitudinal GDMT reduces mortality substantially.

The Four Pillars of GDMT for HFrEF

Four Pillars — Guideline-Directed Medical Therapy ARNI / ACEi / ARB RAAS block Beta-blocker HR / remodel MRA aldosterone SGLT2i glucose / HF Mortality & Hospitalization reverse remodeling over time

The Titration Principle

1
Start low. Begin GDMT at low doses to avoid hypotension and renal stress.
2
Go slow. Double the dose every 2-4 weeks as tolerated.
3
Reach target. Push toward the evidence-based target dose, not just symptom relief.
4
Monitor. Check BP, HR, \( K^{+} \), and renal function (creatinine) at each step.

HFrEF vs HFpEF

HFrEF HFpEF
Ejection Fraction\( \leq 40\% \)\( \geq 50\% \)
Core problemSystolic dysfunctionDiastolic stiffness
Four-pillar GDMTStrong mortality benefitLimited; SGLT2i helps
Typical patientPost-MI, dilatedElderly, HTN, female

The Follow-Up Visit Approach

1
Assess volume. Weight trend, JVP, edema, lung crackles, orthopnea.
2
Review labs. \( K^{+} \), creatinine/eGFR, and BNP/NT-proBNP trends.
3
Titrate GDMT. Uptitrate pillars if BP and renal function allow.
4
Adjust diuretics. Titrate loop diuretic to euvolemia (lowest effective dose).
5
Educate. Daily weights, Na restriction, medication adherence, when to call.

Worked Example: Volume Overload

A 64-year-old man with HFrEF (EF \( 30\% \)) on GDMT reports a 3 kg weight gain over 5 days, new ankle edema, and mild dyspnea. BP 118/72, creatinine stable.

Worked Example: Hyperkalemia

A 70-year-old woman with HFrEF on lisinopril and spironolactone returns. Labs show \( K^{+} = 5.9 \) mEq/L and creatinine rising from 1.0 to 1.6 mg/dL.

Worked Example: Device Eligibility

A 58-year-old man has HFrEF with EF persisting at \( 28\% \) despite 3 months of maximally tolerated GDMT. He remains NYHA class II-III. ECG shows LBBB with QRS \( 158 \) ms.

Common Mistakes

Stopping beta-blocker
Do not discontinue beta-blockers for mild congestion; only reduce in severe decompensation/shock.
Skipping titration
Leaving patients on starter doses forgoes most of the mortality benefit.
Ignoring potassium
ACEi/ARB + MRA can cause dangerous hyperkalemia if not monitored.
Devices too early
ICD/CRT require a full GDMT trial first, not at initial diagnosis.

Longitudinal Care Summary

Element Goal Monitor
GDMTReach target dosesBP, HR, symptoms
DiureticEuvolemiaWeight, edema, JVP
RAAS/MRAMortality benefit\( K^{+} \), creatinine
DevicesEF \( \leq 35\% \) after GDMTECG QRS, NYHA class
EducationSelf-monitoringDaily weights, Na intake

Question 1 of 5

A 60-year-old man with HFrEF (EF \( 32\% \)) is on low-dose carvedilol, lisinopril, and a loop diuretic. He is euvolemic, BP 124/76, \( K^{+} \) and creatinine normal. What is the best next step at this follow-up visit?

Question 2 of 5

A patient with HFrEF on an ACEi and spironolactone returns with \( K^{+} = 6.1 \) mEq/L and rising creatinine. What is the most appropriate action?

Question 3 of 5

A 68-year-old woman with HFpEF (EF \( 58\% \)), hypertension, and type 2 diabetes asks how to lower her risk of HF hospitalization. Which therapy has the best supporting evidence in HFpEF?

Question 4 of 5

A patient with HFrEF reports a 2.5 kg weight gain over 4 days with worsening leg swelling but no chest pain. Vitals and renal function are stable. What is the most appropriate management?

Question 5 of 5

After 3 months of maximally tolerated GDMT, a man's EF remains at \( 30\% \) with NYHA class II symptoms and ECG showing LBBB with QRS \( 156 \) ms. What is the next recommended step?